Comunicados de prensa

8th septiembre 2020

RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.

9th junio 2020

Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe

24th marzo 2020

Curium Announces Approval of Pulmotech^TM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration

12th marzo 2020

RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA

3rd marzo 2020

Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio

7th enero 2020

RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application

2nd diciembre 2019

Curium Acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy

13th noviembre 2019

Curium Announces Plan to Submit an Application to Market Generic Ioflupane I 123 Injection in the U.S.

4th septiembre 2019

Curium Announces Revised Pricing for Technescan MAG3^TM (kit for the preparation of technetium Tc 99m mertiatide)

27th agosto 2018

Curium y RadioMedix anuncian un acuerdo global en exclusiva para el desarrollo de ⁶⁴Cu-Dotatate

10th mayo 2018

Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas

2nd mayo 2018

Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations

11th abril 2018

Curium adquiere las operaciones comerciales y de fabricación de Cyclopharma en Francia.

28th enero 2018

Primer Aniversario de Curium Marcado por Logros Históricos

16th enero 2018

Curium Is the First North American Manufacturer Offering Exclusively 100% LEU Generators

18th diciembre 2017

Renaud Dehareng de Curium recibe el galardón top USA CEO 2017

6th abril 2017

IBA Molecular adquiere Mallinckrodt Nuclear Imaging para crear un grupo de primera clase en la industria radiofarmacéutica

27th enero 2017

IBA Molecular acquires Mallinckrodt Nuclear Imaging to create world-class radiopharmaceuticals Group

24th agosto 2016

IBA Molecular y Mallinckrodt se unen para crear una compañía radiofarmacéutica integrada global